martes, 24 de marzo de 2009

Differences In Neighborhood Food Environment May Contribute To Disparities In Obesity

BMI-unhealthy food stores and restaurants -- although far more abundant than healthy ones -- were not significantly associated with higher BMI or prevalence of obesity.

Almost all of the more than 13,000 adult residents of New York City surveyed lived within a half-mile of an unhealthy food outlet, with an average density of 31 outlets per square kilometer, while 82% lived within a half-mile of a healthy food outlet, with an average density of four outlets per square kilometer. BMI-healthy food outlets are defined as supermarkets and fruit and vegetable markets, and BMI-unhealthy food outlets are fast food restaurants and convenience stores.

The results indicate that a higher density of BMI-healthy food outlets was associated with a lower mean BMI, a lower prevalence of overweight adults, and a lower prevalence of obesity. BMI-unhealthy food stores and restaurants were far more abundant than healthy ones, but the density of these unhealthy food outlets was not significantly associated with BMI or with body size categories. The study indicates that retail outlets providing opportunities for healthier food purchases are associated with lower BMI.

"Given the recent proliferation of initiatives to promote access to supermarkets, farmers markets, and fruit and vegetable stands and to limit fast-food outlets, the study of the causal relationship between the food environment and diet or body size should be a priority for future research," says Andrew Rundle, DrPh, associate professor of Epidemiology at the Mailman School of Public Health, and first author of the study. "I see a role for follow-up studies to examine changes in diet and obesity rates in neighborhoods where new supermarkets or produce stores open."

"Among studies examining the relationship between food environment and body size, this work is among the first to measure the food environment comprehensively," said EHP editor-in-chief Hugh A. Tilson, PhD.

National Health and Nutrition Examination Survey data show that 32% of Americans over the age of 20 are obese. According to the New York City Department of Health and Mental Hygiene statistics, New York City faces a high rate of obesity, and the availability of residential neighborhood resources supporting physical activity and healthy food choices may influence overall obesity rates.

The findings are published in the March 2009 issue of Environmental Health Perspectives.

The study was supported by a grant from the National Institute of Environmental Health Sciences.


Font: http://www.sciencedaily.com/releases/2009/03/090319142433.htm

The Notch Gene Accelerates Colon Carcinogenesis

In mice, abnormal activation of these two signalling pathways increases the number of benign tumours-adenomas-in the intestine by a factor of over twenty compared with activation of the Wnt pathway alone. Moreover, these tumours grow extremely fast in the colon, mimicking the pathogenic process observed in humans. Cooperative action between these two pathways creates a favourable environment for malignant transformation.

These findings (published online in PNAS) show that Notch acts as an "accelerator" in the development of colon cancer in humans, constituting an essential component of the pathogenic process. The question now is to find a "brake" that can counter this.

The gut, which represents a surface area equivalent to that of a tennis court, is in constant turnover completely renewing itself every five days. This turnover depends on the presence of stem cells and progenitor cells found in the crypts between intestinal villi. The stem cells give rise to progenitor cells which can in turn differentiate, over successive division cycles, to give the various different cell types that populate and form the gut. The key factor is to maintain a balance between differentiation and proliferation in the intestinal epithelium.

The Notch and Wnt signalling pathways are important in maintaining this balance, thereby ensuring normal development and organisation in the gut. These two systems control the proliferation and differentiation of stem cells in the intestinal crypts. The Wnt signalling pathway is tightly controlled by the APC (adenomatosis polyposis coli) gene which is associated with early-stage colon carcinogenesis: mutations in one of the two copies of this tumour suppressor gene underlie familial adenomatous polyposis, a condition characterised by the growth of hundreds or even thousands of polyps in the large intestine from adolescence on. This disease accounts for 1% of cases of colon cancer. The vast majority of sporadic cases of colon cancer are also associated with mutations in the APC gene.

The central Notch pathway

The Notch gene product acts as an "On/Off" switch. When it is On, the Notch protein triggers a cascade of intracellular signals essential to the development of all tissues in all multicellular organisms.

Notch is usually qualified as an oncogene and could represent a promising therapeutic target.

Professor Daniel Louvard, working together with Spyros Artavanis-Tsakonas, recently showed that the Notch and Wnt pathways act in concert to control the proliferation of progenitor cells in the gut. In animal models in which Wnt is aberrantly activated, the activation of Notch dramatically accelerates the rate of tumour formation in the gut, especially in the colon. In most mouse models, tumours are rarely found in the colon, unlike in human patients; the development of multiple adenomas in the mouse colon therefore mimics the human pathogenic process.

Such synergy between the Notch and Wnt genes has been observed in different animal models, suggesting that the mechanism is highly conserved throughout evolution. Professor Louvard states that "the Notch gene seems to act as an accelerator of colon carcinogenesis: its activation leads to increased cell division and therefore, an increased likelihood of mutation". However, malignant transformation requires a whole series of genetic events. Aberrant activation of the Notch and Wnt pathways creates a favourable environment for the accumulation of mutations that ultimately lead to colon cancer. Synergy of Notch and Wnt signals contributes to the earliest stages of tumourigenesis-when the tumours are referred to as polyps-the stage at which screening is so important.

Understanding the mechanisms involved in the formation, growth and transformation of these tumours will help in the search for novel therapeutic targets.

In 2005 in France, colon cancer struck more than 37,000 victims and caused 17,000 deaths. The chances of surviving this form of cancer (the third most common malignancy in the country) are closely linked to the stage at which the disease is diagnosed.

A mass colon cancer screening programme was set up at the end of 2008: every two years, everyone betwee n 50 and 74 will be sent a letter inviting them to ask their general practitioner about screening for colon cancer and consider, on a case by case basis, having a test to detect blood in their faeces.

(1) The Morphogenesis & Cell Signalling Group of the Curie Institute Cellular Compartmentalisation & Dynamics Unit; CNRS UMR144

(2) Professeur at the Collège de France and at Harvard Medical School (United States), and Director of the Curie Institute Genetics & Biology of Development Group; CNRS UMR3215/ Inserm U934


Font: http://www.sciencedaily.com/releases/2009/03/090318090437.htm

Genetic Clues Hold Key To Schizophrenia Treatment

The study, conducted by the University of Edinburgh, found that a gene called DISC1 – known to play a role in the development of mental illness – may control the way some patients respond to psychiatric medication.

They also identified seven proteins that are important to the development of mental illness and hope the research could help to create new medicines that target these proteins.

The research was based on existing data from the Human Genome Project, a pioneering study, which mapped all the genes in human DNA.

The team analysed variations of the DISC1 gene and found that it affects a number of other genes that current medications are designed to target.

They believe that by identifying those patients in whom DISC1 may be a root cause of illness, they could find the patients for whom these drugs would be most effective.

The results are published in the Public Library of Science One.

Dr. William Hennah, who led the project at The University of Edinburgh and is now based at the Finland Institute for Molecular Medicine, said: "We know that disorders such as schizophrenia have a genetic element and that this specific gene, DISC1, is important to that process. This research helps us to understand exactly how it affects brain development and provides clues about how to solve problems when that process goes wrong."

Professor David Porteous, of the Institute of Genetics and Molecular Medicine at the University, said: "Schizophrenia is a devastating condition that affects around one in 100 people in the UK. By understanding more fully the genetic processes of mental health and illness we hope to identify ways in which medication might make a real difference to the lives of those affected by these conditions."

The team also hope that their technique of reviewing existing and publicly available genetic data could provide insight into a range of genetically-inherited disorders

This research was funded by the Medical Research Council and the European Molecular Biology Organization.


Font: http://www.sciencedaily.com/releases/2009/03/090319224552.htm

Eating Red And Processed Meat Associated With Increased Risk Of Death

"Meat intake varies substantially around the world, but the impact of consuming higher levels of meat in relation to chronic disease mortality [death] is ambiguous," the authors write as background information in the article.

Rashmi Sinha, Ph.D., and colleagues at the National Cancer Institute, Rockville, Md., assessed the association between meat intake and risk of death among more than 500,000 individuals who were part of the National Institutes of Health-AARP Diet and Health Study. Participants, who were between 50 and 71 years old when the study began in 1995, provided demographic information and completed a food frequency questionnaire to estimate their intake of white, red and processed meats. They were then followed for 10 years through Social Security Administration Death Master File and National Death Index databases.

During the follow-up period, 47,976 men and 23,276 women died. The one-fifth of men and women who ate the most red meat (a median or midpoint of 62.5 grams per 1,000 calories per day) had a higher risk for overall death, death from heart disease and death from cancer than the one-fifth of men and women who ate the least red meat (a median of 9.8 grams per 1,000 calories per day), as did the one-fifth of men and women who ate the most vs. the least amount of processed meat (a median of 22.6 grams vs. 1.6 grams per 1,000 calories per day).

When comparing the one-fifth of participants who ate the most white meat to the one-fifth who ate the least white meat, those with high white meat intake had a slightly lower risk for total death, death from cancer and death from causes other than heart disease or cancer.

"For overall mortality, 11 percent of deaths in men and 16 percent of deaths in women could be prevented if people decreased their red meat consumption to the level of intake in the first quintile [one-fifth]. The impact on cardiovascular disease mortality was an 11 percent decrease in men and a 21 percent decrease in women if the red meat consumption was decreased to the amount consumed by individuals in the first quintile," the authors write. "For women eating processed meat at the first quintile level, the decrease in cardiovascular disease mortality was approximately 20 percent."

There are several mechanisms by which meat may be associated with death, the authors note. Cancer-causing compounds are formed during high-temperature cooking of meat. Meat also is a major source of saturated fat, which has been associated with breast and colorectal cancer. In addition, lower meat intake has been linked to a reduction in risk factors for heart disease, including lower blood pressure and cholesterol levels.

"These results complement the recommendations by the American Institute for Cancer Research and the World Cancer Research Fund to reduce red and processed meat intake to decrease cancer incidence," the authors conclude. "Future research should investigate the relation between subtypes of meat and specific causes of mortality."

This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute.

Editorial: Reducing Meat Consumption Has Benefits Beyond Better Health

"The publication by Sinha et al is timely," writes Barry M. Popkin, Ph.D., of the University of North Carolina, Chapel Hill, in an accompanying editorial. "There is a global tsunami brewing, namely, we are seeing the confluence of growing constraints on water, energy and food supplies combined with the rapid shift toward greater consumption of all animal source foods."

"Not only are components of the animal-source foods linked to cancer, as shown by Sinha et al, but many other researchers have linked saturated fat and these same foods to higher rates of cardiovascular disease," Dr. Popkin writes. "What do we do?"

Because there are health benefits to eating some red and white (although not processed) meats, the consensus is not for a complete shift to vegan or vegetarian diets, Dr. Popkin concludes. "Rather, the need is for a major reduction in total meat intake, an even larger reduction in processed meat and other highly processed and salted animal source food products and a reduction in total saturated fat."

The author is not a vegetarian and has no financial conflict of interest related to any food product as it affects health.


Font: http://www.sciencedaily.com/releases/2009/03/090323161109.htm

Cancer Breakthrough: Tales Of 'Trojan Horse Drug' And 'Miracle Dogs'

Oscar's recovery was extraordinary enough, but his case was unusual for another reason. Oscar is a Bichon Frise, who scientists reporting in Salt Lake City, Utah at the 237th National Meeting of the American Chemical Society on March 23 call "the Miracle Dog." Joseph A. Bauer, Ph.D., and colleagues described promising results with a drug called nitrosylcobalamin (NO-Cbl) in battling cancer in Oscar and three other canines without any negative side effects. While it gives profound hope to dog owners, NO-Cbl also points to a powerful new cancer treatment for humans — one that infiltrates cancer cells like a biological Trojan horse.

"We are one of the few research groups that is offering to treat dogs with cancer that otherwise have no hope," Bauer said. "With no other options available, most people in this situation opt to euthanize so that their pets don't go through the pain of disease and trauma of surgery."

About six million dogs are diagnosed with cancer each year in the United States. According to the National Cancer Institute (NCI), pets with cancer provide a win-win opportunity for cancer researchers. Scientists can study new cancer treatments in animals other than lab mice. And pets get access to new treatments that provide hope and in instances like NO-Cbl, additional time.

Bauer put it this way: "The beauty of using a dog or a cat to test a cancer drug is two-fold. First, the animal can get the benefit of the most up-to-date drug in cancer medicine. Second, the NCI gets data on pets that are exposed to the same environmental factors their owners are. They breathe the same polluted air and drink the same polluted water that you and I do every day. If you can find an agent to treat cancer that occurs in a dog with success, there is a higher likelihood that you can take that to the human population and have a much higher response rate than with mice."

Although NO-Cbl has been used in only a few dogs, daily treatments have led to promising results in each case. "In all four dogs, there has been a significant reduction in tumor size without any toxic side effects or discomfort," says Bauer.

Oscar was the first success story. Since then, Bauer has treated two other dogs. A six-year old golden retriever named Buddy was unable to walk due to a spinal tumor pinching essential nerves leading to his right hind leg. After nine months of daily NO-Cbl treatment, Buddy's tumor shrank by 40 percent and he was going on two mile walks. A 13-year-old female Giant Schnauzer with inoperable thyroid carcinoma also showed tumor reductions of 77 percent in less than 10 weeks.

"Our case studies demonstrate anti-tumor efficacy with limited toxicity to normal tissues," Bauer added. "NO-Cbl sensitizes multidrug-resistant cancer cells to the antitumor effects of several different drugs, so it may be valuable when utilized in combination regimes," he added.

The drug targets cancer cells with "biological Trojan horse technology." Cells have receptors for vitamin B12 on their outer surface. The receptors serve as docking ports where molecules of the vitamin, essential for cells to divide and multiply, attach and then enter the cell. In order to divide at their abnormally rapid pace, cancer cells grow extra B12 receptors — 100 times more than normal cancer cells. Scientists have been trying since the 1950s to exploit that vulnerability and make B12-based drugs that attach to the receptors, sneak into the cell, and deliver a knock-out dose of medication.

Bauer and his colleagues from the Cleveland Clinic attached nitric oxide (NO) molecules to vitamin B12. NO kills cancer cells. The B12 acts as the Trojan horse, easily slipping into cancer cells. The subsequent release of toxic NO kills the cancer cells from within.

The team's goal is to successfully treat 10 dogs with NO-Cbl and slingshot the drug into human use as soon as possible. Because of the genetic similarity between dogs and humans, Bauer says his approach should have a much better chance of getting through the FDA's strict drug approval chain.

But Bauer stresses he wants to get the NO-Cbl dog treatment approved, as well. "I'm committed to the animals, and my goal would be to do a dual clinical trial, Phase One human and Phase One dog," says Bauer.

Oscar is still alive and well. Today, Bauer is treating another Golden Retriever named Haley with a spinal tumor.

"This is one of the most rewarding things I've ever done in my life," says Bauer, the owner of a two-year old Beagle. "It gets boring working in the lab, but to see the fruits of your labor in a positive outcome like this and to know you're responsible in some small way, that's pretty cool."


Font: http://www.sciencedaily.com/releases/2009/03/090323143856.htm

Synthesizing The Most Natural Of All Skin Creams

A protective cream called Vernix caseosa (VC), which covers the fetus and the newborn, aids in the growth of skin both before and after birth. VC provides ‘waterproofing’ in utero, allowing skin to grow in wet conditions, while after birth it hydrates and cleanses, even healing when applied to ulcers. Prof. Joke Bouwstra, a specialist in the skin barrier and its synthesis at Leiden University, and her colleague Robert Ribmann set out to study VC in detail and has produced a synthetic version of this natural buttery ointment which shows the same structure and unique properties. As well as helping pre-term babies develop essential protection against temperature changes, dehydration and infection, artificial VC could also benefit sufferers of skin disease.

Like most moisturising creams, VC is mostly water. Its outstanding properties come from the addition of just 10% each of lipid molecules and dead skin cells (corneocytes), so the exact composition of the mixture is important.

For the lipids, X-ray diffraction measurements at the Dutch/Flemish DUBBLE beamline at the ESRF (European Synchrotron Radiation Facility) allowed the Leiden researchers to find the proportions of the various forms in the cream, even distinguishing between complex molecules differing in chain length.

The corneocytes were also studied using electron microscopy, yielding their size, shape and water content.

But equally important is how the mixture arranges itself. Lipid molecules are shaped something like lollipops, with a round end that prefers to be surrounded by water and a stick which prefers to make a raft with other lollipop sticks. VC contains several different lengths of lipids, which form different arrangements as the temperature changes. The result is that VC fulfils different functions inside and outside the womb, just as butter behaves differently in the oven and on the table. Again, the ESRF’s synchrotron light was used to illuminate the corneocytes and lipids together and look for any clumps or other ordering. Once they knew exactly what VC was made of and how it was arranged, they set about creating a synthetic version.

A readily available natural source of the sort of fat molecules needed is lanolin, the oil found in sheep’s wool, which is currently used as a skin treatment by some nursing mothers. The team isolated the fats which were the closest match to the measurements they had of VC, and used them to create a synthetic solution with the same behaviour. The corneocytes were synthesized by M.H.M. Oudshoorn from the Utrecht University.

When combined, these synthetic ingredients made a cream which looked the same using both x-ray measurements and light microscopy as VC, while allowing the researchers to alter the water content and other properties at will. After pre-clinical testing, the developed creams showed great potential for use on disrupted and underdeveloped skin: the skin barrier recovered much more quickly when synthetic VC was applied.

These promising results will give rise to future clinical studies, in order to prove the benefits of the newly developed creams in treating healthy, dry and diseased human skin.


Font: http://www.sciencedaily.com/releases/2009/03/090317095032.htm

Genomic Fossils In Lemurs Shed Light On Origin And Evolution Of HIV And Other Primate Lentiviruses

During replication, retroviruses integrate within the chromosomes of their host cells. If germ cells are infected, the integrated viral DNA can be transmitted from parent to offspring and may eventually become assimilated as part of the genetic material of the host species. This 'endogenization' process has occurred repeatedly during evolution, and has involved diverse retroviruses, giving rise to a sizeable portion of the genome of many vertebrate species – for example, ~8% of the human genome. Until now, the process was believed to be extremely rare for lentiviruses, an evolutionarily elusive group of retroviruses that infect diverse mammals, including humans (in the form of human immunodeficiency virus [HIV]).

Based on 'fossil' sequences collected from different lemur species, the researchers computationally reconstructed an apparently intact and complete DNA sequence for the ancestral prosimian lentivirus. The discovery that two different species of lemurs endemic to Madagascar suffered, independently and quasi-simultaneously, multiple germline infections of pSIV provides evidence that lentiviruses have repeatedly infiltrated the germline of prosimian species.

These findings should allow future functional analysis of the extinct virus and advance our understanding of the biology of lentiviruses, including HIV. In addition, the characterization of this ancient lentivirus in lemurs raises the possibility that HIV-like retroviruses are still circulating today in the mammalian fauna of Madagascar.



Font: http://www.sciencedaily.com/releases/2009/03/090319224524.htm

Cancer Breakthrough: Tales Of 'Trojan Horse Drug' And 'Miracle Dogs'

Oscar's recovery was extraordinary enough, but his case was unusual for another reason. Oscar is a Bichon Frise, who scientists reporting in Salt Lake City, Utah at the 237th National Meeting of the American Chemical Society on March 23 call "the Miracle Dog." Joseph A. Bauer, Ph.D., and colleagues described promising results with a drug called nitrosylcobalamin (NO-Cbl) in battling cancer in Oscar and three other canines without any negative side effects. While it gives profound hope to dog owners, NO-Cbl also points to a powerful new cancer treatment for humans — one that infiltrates cancer cells like a biological Trojan horse.

"We are one of the few research groups that is offering to treat dogs with cancer that otherwise have no hope," Bauer said. "With no other options available, most people in this situation opt to euthanize so that their pets don't go through the pain of disease and trauma of surgery."

About six million dogs are diagnosed with cancer each year in the United States. According to the National Cancer Institute (NCI), pets with cancer provide a win-win opportunity for cancer researchers. Scientists can study new cancer treatments in animals other than lab mice. And pets get access to new treatments that provide hope and in instances like NO-Cbl, additional time.

Bauer put it this way: "The beauty of using a dog or a cat to test a cancer drug is two-fold. First, the animal can get the benefit of the most up-to-date drug in cancer medicine. Second, the NCI gets data on pets that are exposed to the same environmental factors their owners are. They breathe the same polluted air and drink the same polluted water that you and I do every day. If you can find an agent to treat cancer that occurs in a dog with success, there is a higher likelihood that you can take that to the human population and have a much higher response rate than with mice."

Although NO-Cbl has been used in only a few dogs, daily treatments have led to promising results in each case. "In all four dogs, there has been a significant reduction in tumor size without any toxic side effects or discomfort," says Bauer.

Oscar was the first success story. Since then, Bauer has treated two other dogs. A six-year old golden retriever named Buddy was unable to walk due to a spinal tumor pinching essential nerves leading to his right hind leg. After nine months of daily NO-Cbl treatment, Buddy's tumor shrank by 40 percent and he was going on two mile walks. A 13-year-old female Giant Schnauzer with inoperable thyroid carcinoma also showed tumor reductions of 77 percent in less than 10 weeks.

"Our case studies demonstrate anti-tumor efficacy with limited toxicity to normal tissues," Bauer added. "NO-Cbl sensitizes multidrug-resistant cancer cells to the antitumor effects of several different drugs, so it may be valuable when utilized in combination regimes," he added.

The drug targets cancer cells with "biological Trojan horse technology." Cells have receptors for vitamin B12 on their outer surface. The receptors serve as docking ports where molecules of the vitamin, essential for cells to divide and multiply, attach and then enter the cell. In order to divide at their abnormally rapid pace, cancer cells grow extra B12 receptors — 100 times more than normal cancer cells. Scientists have been trying since the 1950s to exploit that vulnerability and make B12-based drugs that attach to the receptors, sneak into the cell, and deliver a knock-out dose of medication.

Bauer and his colleagues from the Cleveland Clinic attached nitric oxide (NO) molecules to vitamin B12. NO kills cancer cells. The B12 acts as the Trojan horse, easily slipping into cancer cells. The subsequent release of toxic NO kills the cancer cells from within.

The team's goal is to successfully treat 10 dogs with NO-Cbl and slingshot the drug into human use as soon as possible. Because of the genetic similarity between dogs and humans, Bauer says his approach should have a much better chance of getting through the FDA's strict drug approval chain.

But Bauer stresses he wants to get the NO-Cbl dog treatment approved, as well. "I'm committed to the animals, and my goal would be to do a dual clinical trial, Phase One human and Phase One dog," says Bauer.

Oscar is still alive and well. Today, Bauer is treating another Golden Retriever named Haley with a spinal tumor.

"This is one of the most rewarding things I've ever done in my life," says Bauer, the owner of a two-year old Beagle. "It gets boring working in the lab, but to see the fruits of your labor in a positive outcome like this and to know you're responsible in some small way, that's pretty cool."


Font: http://www.sciencedaily.com/releases/2009/03/090323143856.htm

lunes, 23 de marzo de 2009

Obesity Associated With Worse Outcomes After Pancreatic Cancer Surgery

Obesity rates have dramatically increased in the United States over the past 20 years, according to background information in the article. "In many obesity-related diseases and malignant neoplasms [cancerous tumors], an increased prevalence of pancreatic cancer has been reported in numerous epidemiologic and cohort studies focusing on obese patients," the authors write. "Further, obesity has been associated with decreased survival in patients with pancreatic adenocarcinoma, although the mechanism remains unknown."

Jason B. Fleming, M.D., of The University of Texas M. D. Anderson Cancer Center, Houston, and colleagues studied 285 consecutive patients who underwent pancreatic resection (removal of some or all of the pancreas) to treat pancreatic cancer between 1999 and 2006. Data about surgery, patient BMI and outcomes were obtained from the institutional database and electronic medical records.

A total of 152 patients (53 percent) died during a median (midpoint) of 16 months of follow-up. Patients with a BMI higher than 35 survived a median of 13.2 months, compared with 27.4 months for those with a BMI of less than 23. At the last follow-up, 15 of 20 patients (75 percent) with a BMI of more than 35 had died, compared with 137 of 265 patients (52 percent) with a BMI of 35 or less.

"We identified a subset of obese patients (BMI greater than 35) who were at 12-fold risk of lymph node metastasis compared with non-obese patients (BMI of 35 or less). The estimated disease-free and overall survival rates were decreased in the obese patients, and the risk of cancer recurrence and death after pancreatectomy [removal of the pancreas] was nearly twice that in non-obese patients," the authors write. "Cancer recurrence was observed in 95 percent (19 of 20) of patients in the group with a BMI of more than 35 vs. 61 percent (161 of 264) of all other patients."

Previous studies have shown an association between a BMI of more than 35 and an increased risk of death from pancreatic cancer, the authors note. "Our findings extend these observations to those patients who undergo surgery to treat pancreatic cancer and suggest that obesity is a host factor affecting tumor biology independent of the difficulties (patient- and treatment-related) involved in delivering oncologic care in obese patients. Future investigations should include a search for systemic or tumor biomarkers in this group of patients that could provide additional insight."

This study was supported by the Various Donor Fund for Pancreatic Cancer Research and by a grant to the University of Texas M.D. Anderson Cancer Center from the National Institutes of Health.


Font: http://www.sciencedaily.com/releases/2009/03/090316173315.htm

Link Between Religious Coping And Aggressive Treatment In Terminally Ill Cancer Patients

Previous research has shown that more religious patients often prefer aggressive end-of-life (EOL) treatment. The new study –– to be published in the March 18 issue of the Journal of the American Medical Association –– examined whether these patients actually receive such care. The study's findings suggest that physicians tend to comply with religious patients' wishes for more aggressive care.

"Recent research has shown that religion and spirituality are major sources of comfort and support for patients confronting advanced disease," says the study's senior author, Holly Prigerson, PhD, of Dana-Farber and Brigham and Women's Hospital (BWH). "We focused specifically on positive religious coping, on people who rely on their faith to handle the stresses of serious illness and approaching death. Our findings indicate that patients who turn to religion to cope in times of crisis, such as when facing death, are more likely to receive aggressive care when they die."

The study involved 345 advanced cancer patients at seven hospital and cancer centers around the country. Participants were interviewed about their means of coping with the illness, their use of advance care planning tools such as living wills and durable power of attorney, and their preferences regarding end-of-life treatment. Investigators then tracked each patient's course of care during the remainder of his or her life.

An analysis of the data showed that patients identified as positive religious copers had nearly three times the odds of receiving life-prolonging care, in the form of being on a ventilator or receiving cardiopulmonary resuscitation, in the final week of life. Even after researchers accounted for the influence of important factors such as age, ethnicity, or other coping techniques, the connection between religious coping and aggressive EOL care held up.

The researchers also found that religious copers in the study were less likely to have completed advance medical directives, such as a living will or do-not-resuscitate order, which can limit the extent of such interventions in advance. The effects of religious coping on the use of intensive medical care in the last week of life remained significant even after adjusting for differences in advance care planning.

In interpreting the results, study lead author Andrea Phelps, MD, of Dana-Farber and Beth Israel Deaconess Medical Center (BIDMC), and a clinical fellow in medicine at Harvard Medical School, says that "beyond the significance of religious faith in coping with the emotional challenge of incurable cancer, it is important to recognize how religious coping factors into extremely difficult decisions confronting patients as their cancer progresses and death appears imminent. Beyond turning to doctors for advice, patients often look to God for guidance in these times of crisis."

The study did not explore why religious copers often tend to prefer and receive extensive end-of-life care, the authors note. The researchers hope to examine such questions in future studies.

"Our results highlight how patients' ways of coping, particularly their use of religious coping, factor prominently into the ultimate medical care patients receive. This suggests that clinicians should be attentive to terminally ill patients' religious views as they discuss prognosis and treatment options with them," said Prigerson, who is also an associate professor of psychiatry at Harvard Medical School. "A greater understanding of the basis of patients' medical choices can go a long way toward achieving shared goals of care.

Financial support for the study was provided by grants from the National Cancer Institute, the National Institute of Mental Health, and the Fetzer Institute.

The study's co-authors include Deborah Schrag, MD, MPH, Tracy Balboni, MD, Alexi Wright, MD, Elizabeth Trice, MD, and Matthew Nilsson, of Dana-Farber; Paul Maciejewski, PhD, John Peteet, MD, and Susan Block, of Dana-Farber and BWH; and M. Elizabeth Paulk, MD, of the University of Texas Southwestern Medical Center, Dallas.


Font: http://www.sciencedaily.com/releases/2009/03/090317162842.htm

MRSA Study Suggests Strategy Shift Needed To Develop Effective Therapeutics

The study authors suggest that a radical shift may be needed in how scientists should design MRSA therapeutics. Instead of the current focus on neutralizing MRSA by targeting products of mobile genetic elements — DNA molecules that bacteria acquire randomly by interacting with other bacteria — scientists should switch to looking at the permanent DNA backbone (core genome) of USA300 to understand how increased production of certain proteins such as toxins affects its virulence in humans.

NIAID scientist Michael Otto, Ph.D., directed the study, which involved analyzing DNA sequences of the major epidemic forms of S. aureus. The research team found that the lineage of the bacteria fell into three distinct families: (1) USA300 and its forefather, USA500, which are epidemic in U.S. hospital and community settings; (2) MRSA found primarily in hospitals in the United Kingdom and Europe; and (3) MRSA found in hospitals in South America, Europe and Asia.

The researchers then tested the different lineages in mice, observing that the USA300 and USA500 strains were significantly more destructive than the other strains. Further, when interacting with human immune cells, the USA300 and USA500 strains killed nearly 80 percent of the immune cells, compared with a rate of less than 10 percent for all other strains tested. Finally, when the scientists evaluated what in the bacteria was killing the immune cells, they found that levels of alpha toxin and alpha-type phenol-soluble modulins (PSMs) were significantly higher in USA300 and USA500 compared with the other strains. Earlier NIAID studies determined that alpha toxin and alpha-type PSMs play a crucial role in determining the severity of community-associated MRSA infection.

Another important finding of the study, according to Dr. Otto, is that USA300 and USA500 are nearly identical in virulence, as is their level of virulence gene production. This suggests that the Panton-Valentine leukocidin (PVL) and other mobile genetic elements long believed to play key roles in USA300 virulence have no significant impact, because while USA300 carries the PVL and other mobile genes, USA500 does not.

The researchers now are investigating why USA300 is more widespread than USA500 in U.S. community settings, despite their many similarities.

Dr. Otto's collaborators include scientists from NIAID, the University of California at San Francisco and Huashan Hospital, Shanghai Medical College, Fudan University, in China.


Font: http://www.sciencedaily.com/releases/2009/03/090317125226.htm

Mechanism Of Alzheimer's Suggests Combination Therapy Needed

Alzheimer's disease, which may affect as many as 5 million Americans and is among the most costly diseases to society in the United States and Europe, is characterized by two distinctive protein malformations: amyloid plaques and tau tangles. Amyloid plaques are sticky deposits made up of a short protein called amyloid beta, and tau tangles are made of short filaments of the tau protein.

So far no one has been able to explain how amyloid beta and the tau tangles wreak their damage on the nervous system.

"We have known for a long time that amyloid beta was bad," said Scott Brady, professor and head of anatomy and cell biology at the UIC College of Medicine. "What we haven't understood is why it's bad."

The findings, reported in a new study appearing in the Proceedings of the National Academy of Sciences Online Early Edition for March 16-20, suggest promising new targets for combination therapy.

In previous work, published earlier this year, the researchers suggested how tau tangles work together with amyloid beta to create a perfect storm that destroys neural function and memory.

"Cell death occurs at a very late stage of the disease," said Brady, principal investigator of the study. "Long before the cells die they lose function, and that function is critical for the symptoms that we see."

Brady and his colleagues found that when short assemblies of amyloid -- rather than the long-chain plaques -- get inside neurons, they interfere with the cells' transport system. This limits their ability to send vital proteins and vesicles to where they are needed within the cell and interferes with the synaptic connections to other nerve cells.

"We know from study of several hereditary adult-onset neurodegenerative diseases that damage to the transport system, over time, results in loss of synaptic activity, a gradual dying back of the neurons, and eventual neuron death -- exactly the pattern of Alzheimer's disease progression," Brady said.

"Neurons have an enormous logistical problem," Brady said. "Their critical role in making connections may require them to be very large. Some of them have to reach half the body's length -- for a tall person, a meter or more." Even just within the brain, he said, neurons are tremendously long compared to other cells.

The fast axonal transport system responsible for moving proteins and vesicles from the neuron's cell body where they are made, down the long, trunk-like projection of the axon, to the functional areas where they are needed and back again depends on motor proteins that attach to the cargo -- a vesicle or protein -- and carry it along a track made of microtubules.

In the new study, Brady and his colleagues showed that the short assemblies of amyloid activate a transport-regulatory enzyme called CK2 that causes the motor protein to drop its cargo. They were also able to show that inhibition of CK2 is sufficient to prevent the effects of amyloid on transport.

In the earlier work, the researchers showed that tau tangles halt transport to the neuron periphery through other regulatory enzymes by causing the motor protein to release the microtubule track.

The researchers found that the CK2 activated by amyloid also works as a primer for one of the enzymes activated by tau tangles, GSK3.

"Now we have the perfect storm," said Brady. "Both amyloid and tau tangles cause problems. But when you put them together, you exacerbate the problems, creating the cascade of events that cause Alzheimer's loss of neural connections.

"It makes sense of why both have to be present to have Alzheimer's," he said.

"It is also telling us that treating one is not going to be sufficient," he said. "We're going to have to think in terms of combination therapies that will allow us to address many targets at once. This may explain why attempts to manipulate one or the other haven't been successful in patients."

The research was supported in part by grants from the National Institute of Neurological Disorders and Stroke, the Muscular Dystrophy Association, the ALS Association and the American Parkinson Disease Association.

Gustavo Pigino, UIC research assistant professor in anatomy and cell biology, is first author on the new study. Gerardo Morfini, Yuka Atagi, Chunjiang Yu, Lisa Jungbauer and Mary Jo LaDu, all of the UIC College of Medicine, and Atul Deshpande and Jorge Busciglio of the University of California, Irvine, also contributed to the study. Some work was done at the Woods Hole Marine Biological Laboratory in Massachusetts.


Font: http://www.sciencedaily.com/releases/2009/03/090317171948.htm

Severe Vomiting Sickness With Chronic Cannabis Abuse

This obscure clinical manifestation of severe vomiting sickness due to chronic abuse of marijuana was recognized by Dr. Sontineni and his colleagues at the Creighton University of Omaha, NE.

Recent research into the neurobiology of cannabis has led to the identification of different receptor types including two specific types that mediate neuropsychiatric and immunologic effects.

According to Dr. Sontineni, doctors and health care workers currently under recognize the syndrome leading to delayed diagnosis and expensive diagnostic investigations. Increasing consistent use of marijuana among United States populations, particularly young people, over several years will see a steady rise in the number of cases diagnosed each year.

The syndrome was first recognized in Australia around the Adelaide hills. The exact mechanism leading to generation of these symptoms, why it appears only after several years of marijuana abuse and why compulsive hot showering behavior relieves the symptoms is still under scientific investigation.

The recognition of this novel syndrome and increasing physician awareness is supported by the Department of Medicine at Creighton University Medical Center. Similarly, scientists and doctors at other institutions worldwide are beginning to identify more cases with this new syndrome as a result of chronic marijuana abuse among populations.


Font: http://www.sciencedaily.com/releases/2009/03/090320102130.htm

Scientists One Step Closer To Stopping Bone Loss During Spaceflight

Now, by simulating spaceflight conditions through the use of long-duration bedrest, researchers at the University of Washington have found -- for the first time -- a way to prevent bone loss in a specific region of the hip. Using bedrest as an analog of spaceflight, UW scientists are at the mid-point of a study in which 22 volunteers remain in bed, in a six-degree, head-down tilt position for 84 days.

The head-down tilt mimics many of the physiologic adaptations astronauts experience during spaceflight, such as bodily fluid shifts toward the head. The bedrest confinement mimics the complete "unloading" of the musculoskeletal system that astronauts feel as they float through space due to the lack of gravity, which accelerates bone loss. Half of the study participants are randomized to perform individually prescribed intermittent treadmill exercise similar to workouts by astronauts in space -- but with one important difference: they are pulled towards the treadmill surface by a harness applying greater force than what the research team has previously measured during walking and running on the International Space Station treadmill.

"We have found that we can, on average, prevent bone loss in an important region of the hip with this intervention," said Dr. Peter Cavanagh, UW professor of orthopaedics and sports medicine, and principal investigator of the study. "No bedrest study ever before has accomplished this."

The results from the first half of the study are "extremely promising," Cavanagh said. Of the five study subjects so far who have been assigned to the exercise group, bone loss in 4 of the 5 subjects has been prevented in important skeletal regions by the treadmill exercise countermeasure, while the six non-exercising control subject participants all lost bone mass.

Cavanagh said the study results will impact bone health in space and on Earth by better informing exercise prescriptions for astronauts on future space missions, while furthering scientists' understanding of the role individualized exercise programs play in addressing age- and gender-related osteoporosis back on Earth.

Funded by NASA and the National Space Biomedical Research Institute (NSBRI), the study is titled "A Quantitative Test of On-Orbit Exercise Countermeasures for Bone Demineralization Using a Bedrest Analog." The study is expected to move to the NASA Flight Analogs Facility at the University of Texas Medical Branch in Galveston in June 2009. Cavanagh will collaborate with fellow scientists at NASA until the anticipated completion of the study in early 2011. He will discuss the relevance of knowledge gained in space for life on Earth in a keynote address at the International Symposium on Osteoporosis in Washington, DC on April 2, 2009.

For more than 40 years, scientists have known that spaceflight has a detrimental effect on bone, but to date, none of the countermeasures have been 100% effective.

"This study takes us another step closer to learning how to maintain bone health during and after these space missions," Cavanagh said. "This week's launch of the Space Shuttle Discovery serves as a timely reminder that space exploration continues and, with it, our research agenda must keep pace to ensure the musculoskeletal health of our first interplanetary explorers -- as well as the rest us back here at home."


Font: http://www.sciencedaily.com/releases/2009/03/090320150710.htm

New Type Of Botulinum Toxin Appears To Be Well Tolerated And May Help Reduce Forehead Wrinkles

Injecting low doses of Clostridium botulinum toxin type A is a generally accepted method for treating lines on the face, according to background information in the article. A new botulinum toxin type A (Reloxin) has been used to treat neurological disorders outside the United States for more than 15 years and is approved to treat wrinkles in 23 countries. In the United States, this product has been under investigation for the treatment of glabellar or forehead lines since 2002, according to the authors.

Ronald Moy, M.D., of the Moy-Fincher Medical Group, Los Angeles, and colleagues report data from a phase 3, open-label study of 1,200 patients. Investigators injected 0.05 milliliters of solution, each containing 10 units of the new botulinum toxin, into each of five injection sites in the forehead at the beginning of each treatment cycle. Patients maintained diaries of treatment effects, were telephoned seven days later to check for adverse events and were re-examined clinically after two weeks, 30 days and again every month until their next treatment, withdrawal from the study or the end of the study. Based on patient response, as many as five consecutive treatments were given with a minimum of 85 days in between.

A total of 1,052 patients completed the 13-month study. During the study period, 2,838 adverse events were experienced by 880 patients. Of those, 804 (28 percent) were considered probably or possibly related to the treatment, including events at the injection site (18 percent), nervous system disorders (14 percent) such as headache (12 percent) and eye events (9 percent, including 4 percent with ptosis, drooping of the eyelid or brow). Only one patient discontinued the study because of adverse events.

The authors suggest that based on investigators' and patients' assessments, the onset of effect and the duration of effect, the new botulinum toxin type A demonstrated benefits that did not diminish with repeat treatments. "The onset of effect was seen as soon as 24 hours and at a median [midpoint] of three days during all cycles," they write. By day seven of each treatment cycle, 93 percent to 95 percent of patients reported a response to treatment, and between 80 percent and 91 percent had a response by day 30 based on the investigators' assessments.

The authors conclude that multiple cycles of treatment with 50 units of the new botulinum type A toxin were well tolerated and maintained a clinical effect over 13 months and that the incidence of treatment-emergent adverse events decreased over time, showing no evidence of cumulative safety issues after more than 4,000 treatments with this product.

Medicis Pharmaceutical Corp. provided Reloxin and funding for this study. Co-author Dr. Maas owns stock in, has acted as a consultant for and has received research support from Medicis Pharmaceutical Corp.


FOnt: http://www.sciencedaily.com/releases/2009/03/090316173319.htm

Common Anti-seizure Medications May Increase Risk Of Cardiovascular Problems

The team has determined that two of the most commonly prescribed anti-seizure medications may lead to significantly increased levels of cholesterol, C-reactive protein and other markers of cardiovascular disease risk. The finding – set to be published in the March 18th online edition of Annals of Neurology – may help doctors manage the care of patients with seizures more effectively by prescribing different anti-seizure medications that will not adversely affect cardiovascular health.

The study involved two of the most widely-prescribed anticonvulsants – phenytoin (Dilantin®) and carbamazepine (Tegretol®, Carbatrol®) – which have potent effects on many enzymes in the body involved in different areas of metabolism. The researchers recruited 34 epilepsy patients taking either one of those two drugs who were being switched over to one of two newer anti-seizure drugs which do not widely affect enzymes – lamotrigine (Lamictal®) or levetiracetam (Keppra®). The goal was to determine if the change affected the patients' cholesterol levels and other key markers of cardiovascular disease.

Just 6 weeks after the patients' drugs were switched, there were significant declines in total cholesterol, non-high-density lipoprotein (commonly referred to as 'bad') cholesterol, triglycerides and C-reactive protein, suggesting the older, commonly-used drugs might substantially increase the risk of cardiovascular disease.

"The epilepsy patients in this study saw a rapid and clinically significant improvement in several markers related to cardiovascular disease, including a decrease in total cholesterol that averaged 26 points. This is almost certainly not due to some positive effect from the new drugs. It's a consequence of being taken off the older ones, which were causing the cholesterol and other markers to be elevated in the first place," said Dr. Mintzer. "While more investigation is needed, these results may help physicians better understand the risks of these drugs and choose the most appropriate treatment for their epilepsy patients, especially those who are already at risk for cardiovascular disease or have a family history of it."

According to the Epilepsy Foundation, which also funded this study, there are almost three million people living with epilepsy with an additional 200,000 new diagnoses being made each year. Dilantin is the most commonly prescribed anticonvulsant in this country, and has been since its discovery in 1938. Throughout the industrialized world, Tegretol has been the most commonly prescribed anticonvulsant for more than 20 years. The results of this study could have far-reaching effects on how the millions of current, and future patients are, or will be, treated.


Font: http://www.sciencedaily.com/releases/2009/03/090318085928.htm

Longer Bouts Of Exercise Help Prevent Childhood Obesity

Led by Kinesiology and Health Studies professor Ian Janssen, the new study supports Canada’s Physical Activity Guidelines for Children and Youth, which call for children to accumulate at least 90 minutes of moderate-to-vigorous physical activity over the course of the day, in bouts of at least five to 10 minutes’ duration. Until now there has been no scientific evidence to support the recommendation of sustained, rather than sporadic exercise.

“Even in 60-minute physical education classes or team practices, children are inactive for a large portion of the time and this would not necessarily count as sustained exercise,” says Dr. Janssen. “When children engage in longer periods of sustained physical activity, there is a smaller likelihood that they will be overweight or obese.”

The findings appear in the May issue of the American Journal of Preventive Medicine.

Conducted by Dr. Janssen and graduate student Amy Mark, the study analyzed data from 2,498 youth aged eight to 17, who participated in the National Health and Nutrition Examination Survey. Sporadic (one to four minutes), short (five to nine minutes) and medium-to-long (10 minutes and longer) bouts of moderate-to-vigorous physical activity were measured using motion sensors. Participants’ body mass index (BMI) was used to classify them as normal weight or obese.

Two-thirds of the physical activity measured in the young people took place in short, sporadic sessions that lasted less than five minutes. Within the most active children, 25 percent of those who tended to accumulate their physical activity in bouts were overweight or obese, compared with 35 percent in those who tended to accumulate their activity in a sporadic manner.

“Our findings have important public health implications with respect to the promotion of physical activity in young people,” says Dr. Janssen, noting that current U.S. and international guidelines do not stipulate how daily physical activity should be accumulated.

The researchers say that further studies will be required to determine the optimal length of exercise time, and to examine the influence of bouts of physical activity on other aspects of health.


Font: http://www.sciencedaily.com/releases/2009/03/090318113604.htm

Wet Combing More Accurate Than Visual Inspection For Identifying Active Head Lice Infestation

Head lice infestation (pediculosis capitis) is one of the most common childhood infections, affecting between 1 percent and 3 percent of 6- to 12-year-olds in industrialized nations, according to background information in the article. "In view of the high frequency of the infestation and the importance attributed to this parasitic skin disease by caregivers, governesses, teachers and health care providers, it comes as a surprise that the diagnostic accuracy of the techniques currently in use—visual inspection and wet combing—has never been determined appropriately," the authors write. Health care professionals and lay personnel frequently overdiagnose head lice infestation and fail to distinguish between active and extinct cases.

Claudia Jahnke, M.D., of the City Health Department, Braunschweig, Germany, and colleagues compared the two diagnostic methods in 304 students age 6 to 12 attending five German primary schools with head lice epidemics in 2007. Every child attending the schools was examined first by visual inspection, where an applicator stick was used to part the hair at the temples, behind the ears and on the neck. A second investigator, who did not know the results of the inspection, then applied a conditioner to wet the hair and combed from roots to ends with a fine-toothed comb. The conditioner was wiped on white sanitary paper and any object trapped within was examined with a magnifying glass.

Data from visual inspection were available for 304 children and from wet combing for 300 children. The presence of eggs or nits was detected in 79 children (26.3 percent) and lice in trophic stages (adults or nymphs) were seen in 21 children (7 percent).

"Visual inspection underestimated the true prevalence of active infestation by a factor of 3.5," the authors write. Wet combing had a significantly higher sensitivity for detecting active infestations, correctly identifying them in 90.5 percent of the children (vs. 28.6 percent for visual inspections). However, visual inspection had a higher sensitivity for the identification of historic infestations (86.1 percent vs. 68.4 percent).

"In contrast to settings in the developing world in which a high intensity of infestation is the rule, in industrialized countries most children carry only a few lice," the authors write. "In consequence, the optimal detection method should identify even a single louse and should have a high negative predictive value to exclude the possibility that individuals classified as negative for lice are actually false negative with the potential to spread the parasite. In this regard, wet combing is the only useful method if active infestation has to be ruled out."

"Because visual inspection is rapidly performed, requires no additional resources other than a reusable applicator stick and is more sensitive, this technique is the method of choice if the frequency of historic pediculosis capitis is to be determined," they conclude.

This study was partially supported by Ärztekommittee für die Dritte Welt, Frankfurt, Germany, and the Kongregation der Franziskanerinnen, Salzkotten, Germany. Pohl-Boskamp GmbH & Co. KG, Hohenlockstedt, Germany, provided NYDA head lice combs free of charge.


Font: http://www.sciencedaily.com/releases/2009/03/090316173321.htm

Ten Genes Associated With A Risk Factor For Sudden Cardiac Death Identified

That an abnormality in his heart's electrical system had managed to stay on the Q.T. — until it proved lethal — is characteristic of sudden cardiac death, which annually claims more than a quarter million Americans. A dearth of discernable symptoms and lack of detectable molecules circulating in the blood makes the prediction of sudden cardiac death largely dependent on genetic risk factors.

Having identified 10 common variants of genes that modify the timing of the contraction of the heart, known as the QT interval, scientists in the Johns Hopkins University School of Medicine, in collaboration with an international contingent of researchers, now provide new insight about the underpinnings of the QT interval which, when prolonged or shortened, predisposes to sudden cardiac death.

QT interval, which is determined from a standard electrocardiogram (ECG), reflects the time it takes for the heart (ventricles) to contract and then reset for the next heartbeat.

Publishing March 22 in Nature Genetics, the international team including researchers from the Technical University in Munich, Johns Hopkins and others, used DNA samples previously collected for epidemiological studies to analyze the genomes of 15,842 individuals whose QT intervals had been measured by electrocardiogram. With DNA microarray chips, each able to assess hundreds of thousands of markers in each sample, followed by bioinformatic techniques to increase the number of markers, the researchers screened approximately 2.5 million markers to detect subtle alterations in the sequences of these genomes that modify the QT interval.

By focusing on 2.5 million sites in a genome of 3 billion sites, the scientists surveyed one-one-thousandth of nearly 16,000 genomes. This relatively small but "still extremely powerful" screen correlates genomic architecture with QT intervals, according to Aravinda Chakravarti, Ph.D., a professor in the McKusick-Nathans Institute of Genetic Medicine.

These common variants at 10 locations across the genome represent perhaps dozens of yet-to-be-identified genes that affect this trait, Chakravarti adds. Of the 10, one that had been previously identified — Nos1ap — was confirmed. Several others were suspected culprits, the effects of which hadn't been demonstrated in preliminary screens.

"However, almost half were surprising new genes that no one would have guessed as being involved in cardiac biology," says Dan Arking, Ph.D., an assistant professor in the McKusick-Nathans Institute of Genetic Medicine. "So it really does open up a new world of investigation because these are genes that would have never come up if we had only focused on a list of known candidate genes."

A separate study, led by Christopher Newton-Cheh, M.D., M.P.H., of the Massachusetts General Hospital Center for Human Genetic Research and Cardiovascular Research Center , found similar results from more than 13,000 individuals. "We were very reassured to see such strong replication in two independent studies," says Newton-Cheh.

While any single genetic variation in any one individual does not necessarily imply a significant alteration to QT interval, much less increased risk of sudden cardiac death, there is meaning that resides in the collective.

The power of this genetic analysis is a result of screening many thousands of samples, says Chakravarti: "We're not very good at predicting what happens to any one, single sample. It's sort of like, I could examine in great detail how important my vote was in the last election, but it's trivial compared to the collective vote. An individual's genome is important as part of the study's whole, but individually, it's of little consequence."

Likewise, if scientists analyze the effect on QT interval by any one of the genetic variants, the alteration amounts to just a couple milliseconds, which is not a huge amount, says Arking: "But if you put all 10 genetic variants together, that bumps up the QT interval by about 20 milliseconds, which is significant."

This latest study builds on research published in 2006, when a screen of 100,000 sites in individuals of European ancestry first showed that the Nos1ap gene is associated with the QT interval; and subsequent research showing that sequence changes in Nos1ap are also a risk factor for sudden cardiac death. A third paper, published in January 2009 in PLoS one, widened the original screen to include multiethnic populations; that study confirmed that Nos1ap genetic variants alter QT interval in all populations and, in fact, have a stronger effect in women than men.

"The reason people die from this cardiovascular disorder is because we know nothing about the antecedents," Chakravarti says. "It's like a truck barreling down a slope: there's no way to stop it. The only way out is to understand the science of this in a deep, meaningful way. If we know, we can begin to intervene."

The research was supported in part by National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute on Aging, National Institutes of Health, Donald W. Reynolds Cardiovascular Clinical Research Center at Johns Hopkins University, German Federal Ministry of Education and Research, Fondation Leducq, State of Bavaria, Ministry of Health of the Autonomous Province of Bolzano, South Tyrolean Sparkasse Foundation, and the Heinz Nixdorf Foundation.

Authors of the paper, in addition to Chakravarti and Arking, are Georg B. Ehret, Anna Köttgen, W.H. Linda Kao, Josef Coresh and Man Li, Johns Hopkins University; Arne Pfeufer and Christine Happle, Technical University Munich, Germany; Serena Sanna, Gianluca Usala, Mariano Dei, Silvia Naitza and Marco Orrú, Istituto di Neurogenetica e Neurofarmacologia, Cagliari, Italy; Martina Müller and H.-Erich Wichmann, Helmholtz Center Munich; Gerhard Steinbeck and Stefan Kääb, Klinikum Grosshadern, Munich; Gonçalo R. Abecasis and Vesela Gateva, University of Michigan; Christian Fuchsberger, Peter P. Pramstaller and Andrew A. Hicks, EURAC European Academy, Italy; Siegfried Perz, Helmholtz Center Munich; Maja Barbalic and Eric Boerwinkle, University of Texas Health Science Center; Benno Pütz and Bertram Müller-Myhsok, Max Planck Institute of Psychiatry, Munich; Angelo Scuteri, Istituto Ricovero e Cura per Anziani, Rome; Ronald J. Prineas, Wake Forest University School of Medicine; Samer S. Najjar and Edward Lakatta, National Institute on Aging; Thomas W. Mühleisen, University of Bonn; Stefan Möhlenkamp and Karl-Heinz Jöckel, University Hospital of Essen, University Duisburg-Essen; and David Schlessinger, National Institute on Aging.


Font: http://www.blogger.com/post-create.g?blogID=3214599109078920568

How Proteins Find The Right DNA Sequences

In living cells, DNA-binding proteins regulate the activity of various genes so that different cells carry out the right tasks at the right time. For this to work, the DNA-binding proteins need to find the right DNA site sufficiently quickly. The research team behind the new study has previously succeeded in determining that it takes only a few minutes for an individual protein molecule to look through the millions of nearly identical binding alternatives and find the right place to bind. This is nevertheless slower than what is predicted by the established theoretical model for how DNA-binding proteins find their way to the proper place by alternating between diffusing in the cell cytoplasm and along DNA strands.

"By also taking into consideration the fact that there are many obstacles in the way when proteins are to diffuse along DNA strands, we can now calculate more exactly how long it takes them to find their way," says Johan Elf, associate professor of molecular biotechnology at the Center for Bioinformatics.

Besides offering a more precise prediction regarding the time needed to find the right site on DNA, the new theoretical model explains why there is an optimal total concentration of DNA-binding proteins. If there were more, it would simply be impossible for them to find a binding place in a reasonable time, since the proteins would be in each other's way. If there were fewer it would go slower as well, since not enough proteins would be searching. Finally, the new model provides an explanation why so many DNA-binding proteins also bind auxiliary binding sites close to the regulatory site, thus forming DNA loops. It turns out that this can shorten the time to find the right sites.

"This more detailed understanding of gene regulation is important, since it can ultimately provide a better understanding of diseases that occur as a result of problems in the control functions of cells, such as in cancer" says Johan Elf.

The researchers behind the study are Gene-Wei Li, Otto G. Berg, and Johan Elf. The findings are being published March 16 in the scientific journal Nature Physics.a


Font: http://www.sciencedaily.com/releases/2009/03/090316092008.htm

First Automated Carbohydrate 'Assembly Line' Opens Door To New Field Of Medicine

Speaking at the 237th National Meeting of the American Chemical Society, Peter H. Seeberger, Ph.D., described development of an automated carbohydrate synthesizer, a device that builds these intricate molecules in a few hours — rather than the months or years required with existing technology.

"Our automated synthesizer is now the fastest method to make complex carbohydrates," says Seeberger, principal investigator for the research. "There are currently no competitive methods available. Today, if people working in biology run into a problem related to carbohydrates, they usually drop it because there are no tools available. They can't buy anything from a catalogue. It becomes a royal pain in the neck."

Scientists trying to synthesize DNA and protein-based molecules experienced a similar pain-in-the neck decades ago, until the invention of automated DNA and protein synthesizers. These devices helped kick start a revolution in genetics and proteomics. The carbohydrate synthesizer may do the same thing for the emerging fields of glycochemistry and glycobiology — named for carbohydrate sugar chains known as "glycans."

In 2001, Seeberger and colleagues reported the design of a prototype synthesizer. Revealed for the first time at the ACS National Meeting, the latest version is now fully automated, much faster, and can be operated by a non-expert, says Seeberger. Developed at the Swiss Federal Institute of Technology in Zurich, the instrument produces significant quantities of carbohydrate molecules that were nearly inaccessible until now.

Carbohydrates are tough molecules to build because of their complicated, branched structure. So instead of trying to build carbohydrates from scratch, scientists today use molecules isolated from nature, a painstaking process that could take months.

"We make things chemically that people used to isolate," explains Seeberger. "The automated synthesizer puts single sugars, the building blocks of carbohydrates, together like beads on a string."

Carbohydrates play crucial roles in the immune system, especially in the body's defenses against disease-causing viruses and bacteria. Most of these microbes have unique carbohydrate markers on their surfaces. The immune system recognizes these carbohydrates as foreign material, and creates antibodies that launch an immune response to battle the infection.

"Vaccines 'educate' the immune system to recognize a specific molecule on the surface of infectious organisms," explains Seeberger. "The synthesizer allows us to make not one but many carbohydrate structures from a particular organism and test those to see if they protect against the microbe. Synthetic carbohydrates that show promising protective qualities then may become the basis for new vaccines.

In a recent finding, the team discovered a carbohydrate on the surface of the malaria parasite P. falciparum that enables the parasite to infect human red blood cells, thus solving a long-standing mystery about how infection happens.

Seeberger's group used the carbohydrate synthesizer to develop a malaria vaccine. Clinical trials for the vaccine are scheduled for 2010 in Mozambique and Tanzania. Its unique "anti-disease" mechanism makes it the only vaccine of its kind, he says.

"To my knowledge, ours is the first attempt at an anti-disease vaccine. It doesn't actually kill the malarial parasite; it blocks its toxic action. You create antibodies against the sugar structure, and these antibodies block the carbohydrate toxin from leading to inflammation and anemia, the hallmarks of malarial infection," says Seeberger.

He explained that they will pair the carbohydrate vaccine with a traditional, protein-based one to create a "conjugate vaccine," which is best suited to immunize the most vulnerable group of potential malaria victims — children under the age of two.

The malaria vaccine is only one of almost a dozen vaccines from Seeberger's lab headed for clinical trials. Carbohydrate-based vaccines could target some of today's most serious infectious diseases, including antibiotic-resistant infections and HIV.

Seeberger is commercializing the carbohydrate synthesizer through his start-up company, Ancora Pharmaceuticals, based in Medford, Mass. Looking ahead, Seeberger discussed the other major obstacle facing carbohy¬¬¬drate research.

"In the area of glycobiology, there are two technological hurdles right now. One is to get access to molecules, which we have now addressed. The second one is sequencing. If you look at the human genome project, or genomics and proteomics, sequencing and synthesis were always the key issues," says Seeberger.

Seeberger saw firsthand the profound effect that automated DNA synthesizers had on genetics and biotechnology. His doctoral advisor, Marvin H. Caruthers, Ph.D., of the University of Colorado, helped develop the first model in 1980.

"We hope that we have the same effect on carbohydrate research," says Seeberger.


Font: http://www.sciencedaily.com/releases/2009/03/090322154409.htm

Genetic Mechanism In Mole Rats Can Be Targeted In Cancer Research

This landmark discovery was revealed in a new study carried out by researchers from the Institute of Evolution at the University of Haifa and the Functional Genomics Center at the University of Illinois.

"When we understand how the subterranean mole rat developed these mechanisms for survival, we may be able to understand why they are so destructive in humans," Prof. Aaron Avivi of the University of Haifa said.

The biological significance of the blind subterranean mole rat was recognized about 50 years ago by Prof. Eviatar Nevo, who also pioneered biological studies of the organism. The current study, led by Prof. Aaron Avivi from the Institute of Evolution at the University of Haifa and Dr. Mark Band from the University of Illinois, is supported by a grant from the U.S-Israel Binational Science Foundation (BSF), and has just been published in the online FASEB Journal.

Based on the new study, the mole rat can represent the human tumor in research, and the gene targeted in mole rats can be targeted for possible development of anti-cancer drugs. It is therefore predicted that understanding the survival mechanism in the blind subterranean mole rat can help in the advancement of cancer research. "When we understand how the subterranean mole rat developed these mechanisms for survival, we may be able to understand why they are so destructive in humans," Prof. Avivi of the University of Haifa pointed out.

Experiments were conducted on groups of hypoxia-tolerant mole rats and hypoxia-intolerant "regular" rats. A group of each species was exposed to normal levels of oxygen while other groups were exposed to low oxygen levels, ranging from 3 to 10 percent. The gene BNIP3, which becomes active in the regular rats to protect their bodies from low oxygen and to prevent resulting damage, was shown to be active in heart and skeletal muscles. On the other hand, in the mole rats that tolerate low levels of oxygen, the gene was less expressed and less active, suggesting and supporting previous findings by these scientists that on a physiological level their cells and tissues do not become hypoxic.

The hypoxia-regulated pattern of BNIP3 expression and the gene's activity in the mole rat echoes its behavior in cancer cells. In both cases waves of normal oxygen levels and hypoxic levels lead to changes in the regulation of hypoxia-induced genes behavior. In mole rats this fluctuation is due to rainfalls that flood their underground tunnels, limiting the availability of oxygen and, moreover, forcing them to rebuild the tunnels and exhaust the limited oxygen; in tumor cells it occurs as they divide faster than blood vessels, which supply oxygen, sprouting into new cells.

Among a growing list of hypoxia-induced genes that were studied in the mole rat by Prof. Avivi and his colleagues and collaborators, this is the third gene that shows a similar pattern of expression as in cancer. In the past it has also been revealed that VEGF (Vascular Endothelial Growth Factor - a major growth factor that regulates the growth of new blood vessels) and p53 (a "master" gene, responsible for activating a battery of other genes engaged in either programmed cell death [apoptosis] or DNA-repair in cells) exhibit a similar mode of action in mole rats and in cancer growths, which is why they are so destructive in human cancer growths, Prof. Avivi pointed out.


Font: http://www.sciencedaily.com/releases/2009/03/090315223845.htm

Mice With Disabled Gene That Helps Turn Carbs Into Fat Stay Lean Despite Feasting On High-carb Diet

The authors of the study, to be published in the March 20 issue of the journal Cell, say the gene, called DNA-PK, could potentially play a role in the prevention of obesity related to the over-consumption of high-carbohydrate foods, such as pasta, rice, soda and sugary snacks.

DNA-PK, which stands for DNA-dependent protein kinase, has already been the subject of much research because it helps repair breaks in the DNA. Suppression of DNA-PK has been used as a technique by researchers to enhance the ability of cancer treatments to kill tumor cells. Its role in fat synthesis, then, came as a surprise to the UC Berkeley researchers.

"It turns out that DNA-PK is critical to a metabolic process we have been trying to understand for 20 years," said Hei Sook Sul, a professor in UC Berkeley's Department of Nutritional Science & Toxicology and head of the research team behind these new findings. "For the first time, we have connected DNA-PK to the signaling pathway involved in the formation of fat from carbohydrates in the liver. Identifying this signaling pathway involving DNA-PK brings us one step forward in understanding obesity resulting from a diet high in carbohydrates, and could possibly serve as a potential pharmacological target for obesity prevention."

After a meal of pizza and soda, it is known that levels of blood glucose - the digested form of carbohydrates - go up. That rise in blood glucose triggers the secretion of the hormone insulin, which helps different cells in the body use glucose for energy. Glucose in the liver that isn't burned for energy turns into fatty acids, which then circulate to other parts of the body, primarily to fat tissue.

This conversion of excess glucose into fatty acids occurs in the liver, but the exact molecular pathway involved has not been fully understood until now. Researchers have known that insulin binds to receptors on the liver cells, which activates protein phosphatase-1 (PP1), the first molecule of the insulin-signaling pathway inside the liver cell. Sul's lab had previously shown that upstream stimulatory factor (USF) is needed to activate certain genes, such as fatty acid synthase (FAS), which converts glucose to fatty acids.

The link between PP1 and USF was still a mystery until Roger H. F. Wong, a UC Berkeley graduate student in comparative biochemistry in Sul's lab, finally connected the dots through proteomic sequencing. He found that DNA-PK, which is regulated by PP1, controls the activation of USF and the subsequent conversion of glucose to fatty acids.

"The missing link was DNA-PK," said Wong. "We determined that DNA-PK acts as a signaling molecule in the chain reaction that begins when insulin binds to receptors on liver cells. This helps explain why untreated Type 1 diabetics, who cannot produce insulin, may experience significant weight loss. Without treatment, they basically have trouble making enough fat."

"This insulin-signaling pathway is also disrupted in Type 2 diabetes, in which the body still produces insulin, but the cells become resistant to its effects," said Wong.

After identifying DNA-PK, the researchers put the gene to the test in mice fed a diet containing 70 percent carbohydrates, but no fat. A typical lab mouse diet is made up of both fat and carbohydrates. Half the mice had the DNA-PK gene disabled, and the other half comprised a control group of normal mice.

"The DNA-PK disabled mice were leaner and had 40 percent less body fat compared with a control group of normal mice because of their deficiency in turning carbs into fat," said Wong. "The knockout mice were resistant to high carbohydrate-induced obesity and had lower plasma lipids, which can reduce the risk of cardiovascular disease. With all of these health benefits, this gene can serve as a potential pharmacological target for obesity prevention."

The researchers noted that although interest in low-carb diets persists, there are many sources of carbohydrates, including fruits and vegetables, legumes and whole grain breads and pastas, that have important nutritional benefits.

"The best way to control your body weight is to eat a well-balanced diet and limit your caloric intake," said Wong. "We hope that this research will one day help people eat bread, pasta and rice and not worry about getting fat."

This study is part of the larger research effort by the Sul lab to understand the molecular mechanisms underlying the synthesis of fatty acids, creation of fat cells and how fat is stored in the body. Recently, the lab published a study in the journal Cell Metabolism describing how a molecule called Pref-1 blocks the creation of fat cells. Two months ago, the discovery by Sul's lab of an enzyme called AdPLA critical to the breakdown of fat cells, was published in the journal Nature Medicine. This latest paper in Cell details the very first step of fat synthesis - making fat from carbohydrate.

Other co-authors of this study are members of Sul's lab and include several undergraduate students in the Department of Nutritional Science & Toxicology.

The National Institutes of Health helped support this study in Cell.


Font: http://www.sciencedaily.com/releases/2009/03/090319132919.htm